Publicaciones en colaboración con investigadores/as de University of Genoa (15)

2019

  1. Nailfold capillaroscopy characteristics of antisynthetase syndrome and possible clinical associations: Results of a multicenter international study

    Journal of Rheumatology, Vol. 46, Núm. 3, pp. 279-284

2018

  1. Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: A pooled analysis of the PALACE 1-3 studies

    RMD Open, Vol. 4, Núm. 1

  2. Timing of onset affects arthritis presentation pattern in antisynthetase syndrome

    Clinical and Experimental Rheumatology, Vol. 36, Núm. 1, pp. 44-49

2017

  1. A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis

    American Journal of Human Genetics, Vol. 100, Núm. 1, pp. 64-74

  2. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update

    Annals of the Rheumatic Diseases, Vol. 76, Núm. 6, pp. 960-977

  3. EULAR/PReS standards and recommendations for the transitional care of young people with juvenile-onset rheumatic diseases

    Annals of the Rheumatic Diseases, Vol. 76, Núm. 4, pp. 639-646

2016

  1. Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: Results of two Phase 2 randomised controlled trials

    Clinical and Experimental Rheumatology, Vol. 34, Núm. 3, pp. 430-442

2015

  1. A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility

    American Journal of Human Genetics, Vol. 96, Núm. 4, pp. 565-580

  2. Long-Term Safety, Efficacy, and Quality of Life in Patients With Juvenile Idiopathic Arthritis Treated With Intravenous Abatacept for Up to Seven Years

    Arthritis and Rheumatology, Vol. 67, Núm. 10, pp. 2759-2770

2013

  1. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions

    Annals of the Rheumatic Diseases, Vol. 72, Núm. 4, pp. 482-492

2012

  1. Treating rheumatoid arthritis to target: Recommendations of an international task force

    Revmatologiia (Bulgaria), Vol. 20, Núm. 2, pp. 5-16

2010

  1. Current evidence for the management of rheumatoid arthritis with glucocorticoids: A systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis

    Annals of the Rheumatic Diseases, Vol. 69, Núm. 6, pp. 1010-1014

  2. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

    Annals of the Rheumatic Diseases, Vol. 69, Núm. 6, pp. 964-975

  3. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis

    Arthritis and Rheumatism, Vol. 62, Núm. 6, pp. 1792-1802

  4. Treating rheumatoid arthritis to target: Recommendations of an international task force

    Annals of the Rheumatic Diseases, Vol. 69, Núm. 4, pp. 631-637